Jason Efstathiou, Vice President at Radiation Oncology Institute (ROI) – The ASTRO Foundation, shared a post on X:
“Honored to present this morning at the joint IBCG–GSRGT Bladder Cancer Variant Histology Meeting in Tampa alongside Tom Flaig.
We reviewed prior clinical trials in this space – highlighting lessons in eligibility, accrual, pathologic QA, and endpoints-and discussed how these insights can shape smarter study designs moving forward. Variant histology bladder cancer ≠ one disease.”
Philippe Spiess, Assistant Chief of Surgery and Senior Member at Deptartment of GU Oncology at Moffitt Cancer Center, shared Jason Efstathiou’s post, adding:
“Exceptional meeting with close friends and thought leaders. All dedicated to advancing the fundamental knowledge and treatment standards of bladder cancer variant histologies.
A huge unmet need. Thanks everyone for being part of this important effort.”
More from Jason Efstathiou on OncoDaily.
